The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers-Reference-Cited by-同舟云学术

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers

Published:2018-05 Issue:5 Volume:28 Page:643-655
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Moschetti Viktoria,Kim Maria,Sand Michael,Wunderlich Glen,Andersen Grit,Feifel Ulrich,Jang In-Jin,Timmer Wolfgang,Rosenbrock Holger,Boland Katja

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology

Reference16 articles.

1. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer's disease;Bales,2010

2. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers;Boland;Hum. Psychopharmacol.,2017

3. Plasticity in the human central nervous system;Cooke;Brain,2006

4. BI 409306, A novel phosphodiesterase 9A inhibitor, Part I: potency, selectivity and in-vitro functional characterization on synaptic plasticity;Dorner-Ciossek;Schizophr. Bull.,2015

5. Role of PDE9 in Cognition;Dorner-Ciossek;Adv. Neurobiol.,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Discovery and Development Targeting Dementia;Pharmaceuticals;2023-01-19

2. The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study;European Journal of Clinical Pharmacology;2022-01-28

3. Increased Energy Expenditure and Protection From Diet-Induced Obesity in Mice Lacking the cGMP-Specific Phosphodiesterase PDE9;Diabetes;2021-10-07

4. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery;Journal of Medicinal Chemistry;2021-05-27

5. Increased energy expenditure and protection from diet-induced obesity in mice lacking the cGMP-specific phosphodiesterase, PDE9;2021-02-02